Diabetes News and Research

Latest Diabetes News and Research

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.

10 Aug 2010

Mild sleep restriction for several nights can affect cognitive tasks: Research

Many people are sleep restricted, either because they have to or because they choose to be, she says. "Instead of going to bed when they are tired, like they should, people watch TV and want to have an active social life," she says. "People count on catching up on their sleep on the weekends, but it may not be enough."

10 Aug 2010

Ratios between males and females affect human longevity: Study

"Love stinks!" the J. Geils band told the world in 1980, and while you can certainly argue whether or not this tender and ineffable spirit of affection has a downside, working hard to find it does. It may even shorten your life.

10 Aug 2010

Researchers find disparities among children suffering from repeated ear infections

Research has documented that ethnic and socioeconomic disparities exist among patients with conditions such as heart disease and diabetes. Now, a new study by researchers from UCLA and Harvard University has found disparities among children suffering from repeated ear infections. The findings, published in the August edition of the journal Laryngoscope, show that frequent ear infections plague white children and children living below the poverty level more than children of other racial or ethnic backrounds or income levels.

10 Aug 2010

New insight into protein transport mechanism can improve chemotherapy treatments

A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).

10 Aug 2010

New microchip technology to detect oral cancer

A new test for oral cancer, which a dentist could perform by simply using a brush to collect cells from a patient's mouth, is set to be developed by researchers at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2010. The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified.

9 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Remote monitoring of chronic heart failure patients can reduce pressure on resources

Providing patients with chronic heart failure access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. These are the conclusions of a new Cochrane Systematic Review by an international team of researchers.

9 Aug 2010

Myths and realities of Medicare bidding program for durable medical equipment

Providers of home medical equipment and services across California are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of California's 4.6 million Medicare beneficiaries, and put thousands of California homecare providers out of business.

7 Aug 2010

Researchers examine differences in eating habits of African Americans

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

Diabetes News and Research

Latest Diabetes News and Research

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Mild sleep restriction for several nights can affect cognitive tasks: Research

Ratios between males and females affect human longevity: Study

Researchers find disparities among children suffering from repeated ear infections

New insight into protein transport mechanism can improve chemotherapy treatments

New microchip technology to detect oral cancer

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

Isis second-quarter pro forma net operating loss increases to $15.5 million

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Remote monitoring of chronic heart failure patients can reduce pressure on resources

Myths and realities of Medicare bidding program for durable medical equipment

Researchers examine differences in eating habits of African Americans

Orexigen second-quarter net loss decreases to $11.9 million

Halozyme second-quarter revenue increases to $3.2 million

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in